People with the subtype of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) associated with fusion of MEF2D with other genes show quite poor prognosis. Most patients fail to respond to hematopoietic stem cell transplantation or other conventional treatments. Researchers at Shanghai Jiao Tong University School of Medicine have reported a lead compound that could treat BCP-ALL.